- Home
- LNG vs ALNY Comparison
LNG vs ALNY Comparison
Compare LNG & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNG
- ALNY
- Stock Information
- Founded
- LNG 1983
- ALNY 2002
- Country
- LNG United States
- ALNY United States
- Employees
- LNG N/A
- ALNY N/A
- Industry
- LNG Oil/Gas Transmission
- ALNY Biotechnology: Pharmaceutical Preparations
- Sector
- LNG Utilities
- ALNY Health Care
- Exchange
- LNG Nasdaq
- ALNY Nasdaq
- Market Cap
- LNG 51.8B
- ALNY 59.6B
- IPO Year
- LNG 1997
- ALNY 2004
- Fundamental
- Price
- LNG $235.21
- ALNY $462.11
- Analyst Decision
- LNG Strong Buy
- ALNY Strong Buy
- Analyst Count
- LNG 13
- ALNY 28
- Target Price
- LNG $262.77
- ALNY $424.22
- AVG Volume (30 Days)
- LNG 1.6M
- ALNY 1.1M
- Earning Date
- LNG 10-30-2025
- ALNY 10-30-2025
- Dividend Yield
- LNG 0.85%
- ALNY N/A
- EPS Growth
- LNG N/A
- ALNY N/A
- EPS
- LNG 17.11
- ALNY N/A
- Revenue
- LNG $18,231,000,000.00
- ALNY $2,461,963,000.00
- Revenue This Year
- LNG $34.48
- ALNY $58.97
- Revenue Next Year
- LNG $14.00
- ALNY $38.81
- P/E Ratio
- LNG $13.79
- ALNY N/A
- Revenue Growth
- LNG 14.42
- ALNY 5.01
- 52 Week Low
- LNG $176.56
- ALNY $205.87
- 52 Week High
- LNG $257.65
- ALNY $484.21
- Technical
- Relative Strength Index (RSI)
- LNG 47.65
- ALNY 62.07
- Support Level
- LNG $231.68
- ALNY $444.66
- Resistance Level
- LNG $240.15
- ALNY $475.69
- Average True Range (ATR)
- LNG 4.34
- ALNY 11.96
- MACD
- LNG -0.47
- ALNY -2.68
- Stochastic Oscillator
- LNG 26.69
- ALNY 48.24
About LNG Cheniere Energy Inc.
Cheniere Energy is a liquified natural gas, or LNG, producer with two facilities in Corpus Christi, Texas and Sabine Pass, Louisiana. It generates most of its revenue through long-term contracts with customers on a fixed and variable fee payout structure. It also generates revenue by selling uncontracted LNG to customers on a short or one-time basis. A subsidiary, Cheniere Energy Partners, owns the Sabine Pass facility and trades as a master limited partnership.
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.